Verdict: Side-by-side breakdown using the Bull Rankings model. DOC scored 67.0, SBRA scored 68.0 — SBRA leads.
Compare another set
DOC
Healthpeak Properties, Inc.
REIT - Healthcare Facilities · Financial strength
71.6Fin
$18.77 · $13.3B
fundamentals as of
Strength gap
3.2
DOC leads
SBRA
Sabra Health Care REIT, Inc.
REIT - Healthcare Facilities · Financial strength
68.4Fin
$19.21 · $4.9B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
Fastest growthSBRA+10.2%
Strongest balance sheetSBRA0.96
Side by side · every name on one set of axes
Fundamentals, head-to-head
DOC
SBRA
6.5%A-
Yield
6.3%A-
+4.5%C+
Rev
+10.2%B
1.09B
D/E
0.96B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
The companies
DOCHealthpeak Properties, Inc.
REIT - Healthcare Facilities · $18.77 · beta 0.99
Why now
REIT - Healthcare Facilities · market cap $13.3b. 18% off the 52-week high of $22.95. 19 sell-side analysts rate this a Buy with a mean 1-yr target of $22.95 (implying +22% upside).
Moat
Moat signals from the quantitative card are modest — profitability and capital efficiency are middle-of-pack. The thesis here depends on softer factors (switching costs, brand, distribution, regulatory protection) not captured by the quality-growth screen.
Risk
Dividend payout 349% of earnings on a 6.5% yield — distribution coverage is thin; one earnings stumble could force a dividend cut. ROE 3% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
SBRASabra Health Care REIT, Inc.
REIT - Healthcare Facilities · $19.21 · beta 0.62
Why now
REIT - Healthcare Facilities · market cap $4.9b. 16% off the 52-week high of $22.77. Revenue growing +10%, comfortably above the S&P median. 14 sell-side analysts rate this a Buy with a mean 1-yr target of $22.79 (implying +19% upside).
Moat
Moat signals from the quantitative card are modest — profitability and capital efficiency are middle-of-pack. The thesis here depends on softer factors (switching costs, brand, distribution, regulatory protection) not captured by the quality-growth screen.
Risk
Dividend payout 480% of earnings on a 6.3% yield — distribution coverage is thin; one earnings stumble could force a dividend cut. ROE 2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Common questions
Is SBRA or DOC the better stock?
SBRA scores higher: SBRA 68.0, DOC 67.0 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
How are SBRA and DOC scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.